<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>439</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>12610629</PubmedId>
            <Abstract>HER2 (also known as Neu, ErbB2) is a member of the epidermal growth factor receptor (EGFR; also known as ErbB) family of receptor tyrosine kinases, which in humans includes HER1 (EGFR, ERBB1), HER2, HER3 (ERBB3) and HER4 (ERBB4). ErbB receptors are essential mediators of cell proliferation and differentiation in the developing embryo and in adult tissues, and their inappropriate activation is associated with the development and severity of many cancers. Overexpression of HER2 is found in 20-30% of human breast cancers, and correlates with more aggressive tumours and a poorer prognosis. Anticancer therapies targeting ErbB receptors have shown promise, and a monoclonal antibody against HER2, Herceptin (also known as trastuzumab), is currently in use as a treatment for breast cancer. Here we report crystal structures of the entire extracellular regions of rat HER2 at 2.4 A and human HER2 complexed with the Herceptin antigen-binding fragment (Fab) at 2.5 A. These structures reveal a fixed conformation for HER2 that resembles a ligand-activated state, and show HER2 poised to interact with other ErbB receptors in the absence of direct ligand binding. Herceptin binds to the juxtamembrane region of HER2, identifying this site as a target for anticancer therapies.</Abstract>
            <ArticleYear>2003</ArticleYear>
            <ArticlePages>756-60</ArticlePages>
            <ArticleTitle>Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Cho</LastName>
                    <ForeName>Hyun-Soo</ForeName>
                </Author>
                <Author>
                    <LastName>Mason</LastName>
                    <ForeName>Karen</ForeName>
                </Author>
                <Author>
                    <LastName>Ramyar</LastName>
                    <ForeName>Kasra X</ForeName>
                </Author>
                <Author>
                    <LastName>Stanley</LastName>
                    <ForeName>Ann Marie</ForeName>
                </Author>
                <Author>
                    <LastName>Gabelli</LastName>
                    <ForeName>Sandra B</ForeName>
                </Author>
                <Author>
                    <LastName>Denney</LastName>
                    <ForeName>Dan W</ForeName>
                    <Suffix>Jr</Suffix>
                </Author>
                <Author>
                    <LastName>Leahy</LastName>
                    <ForeName>Daniel J</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Biophysics and Biophysical Chemistry, The Johns Hopkins University School of Medicine, 725 North Wolfe Street, Baltimore, Maryland 21205, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antibodies, Monoclonal, Humanized;Immunoglobulin Fab Fragments;Ligands;Receptor, ErbB-2;Trastuzumab</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Monoclonal(chemistry; immunology); Antibodies, Monoclonal, Humanized; Binding Sites; Binding Sites, Antibody; Crystallography, X-Ray; Humans; Immunoglobulin Fab Fragments(chemistry; immunology); Ligands; Models, Molecular; Protein Structure, Tertiary; Rats; Receptor, ErbB-2(chemistry; immunology); Trastuzumab</ArticleMeshHeadingsList>
            <Journal>
                <Volume>421</Volume>
                <Issue>6924</Issue>
                <Title>Nature</Title>
                <Issn>1476-4687</Issn>
                <MedlineTa>Nature</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Herceptin Fab epitope of ErbB2 (HER2)</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>P579, E580, A581, D582, Q583, D592, P593, P594, F595, K615, F616, P617, D618, E619, E620, G621, A622, C623, Q624, P625</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>P04626.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>9606</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>PDB 1N8Z</LocationOfData>
                <EpitopeId>77264</EpitopeId>
                <ReferenceRegion>P557, E558, A559, D560, Q561, D570, P571, P572, F573, K593, F594, P595, D596, E597, E598, G599, A600, C601, Q602, P603</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 4, Supplementary Table 1 and PDB 1N8Z</LocationOfData>
                        <BCellId>1984</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Sex>F</Sex>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>P04626.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>9606</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HER2</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <TransfectedCell>
                                        <SubType>Transfected Cell</SubType>
                                        <CellType>Fibroblast</CellType>
                                        <CellSourceOrganismId>10090</CellSourceOrganismId>
                                    </TransfectedCell>
                                </ImmunogenContainingObject>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>4 doses of 1 x 10&lt;sup&gt;7&lt;/sup&gt; cells on weeks 0, 2, 5 and 7 and a partially purified Triton X-100 membrane preparation of HER2 on weeks 9 and 13</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>The monoclonal antibody Herceptin (trastuzumab) is commercially produced (Genentech). The parent monoclonal antibody 4D5 was generated in mice immunized with the mouse fibroblast cell line NIH 3T3/HER2-3(400), expressing high levels of HER2, as described in the reference: Hudziak et al. (1989) Mol Cell Biol 9(3): 1165-72 [PMID: 2566907]. The antibody was humanized by fusing the antibody binding regions to the framework regions of human IgG1 heavy and kappa light chains to generate Herceptin (trastuzumab) as described in the reference: Carter et al. (1992) Proc Natl Acad Sci U S A 15;89(10): 4285-9 [PMID: 1350088].</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.52</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope of Herceptin Fab on the extracellular region (domains I-IV) of human HER2 was determined from the crystal structure of the complex, solved by molecular replacement.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Antibody construct</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>anti-ErbB2 antibody Herceptin (trastuzumab) Fab</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Herceptin</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1N8Z_B</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1N8Z_A</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>Receptor tyrosine-protein kinase erbB-2, extracellular domains</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Fragment of Source Antigen</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>TQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTNASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGLRELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGESSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNTDTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGLGMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWPDSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLFRNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREYVNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGACQPCPIN</LinearSequence>
                                        <StartingPosition>23</StartingPosition>
                                        <EndingPosition>629</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P04626.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>9606</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1N8Z</ComplexPdbId>
                            <AntibodyChain1PdbChain>B</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>A</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>C</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <Comments>Paratope residues and contacts are not provided in the reference.</Comments>
                            <CuratedContacts>
                                <EpitopeResidues>C: P557, E558, A559, D560, Q561, D570, P571, P572, F573, K593, F594, P595, D596, E597, E598, G599, A600, C601,Q602, P603</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>A: ; B: ;</AntibodyResiduesInteractingWithAntigen>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>C: P557, E558, D560, Q561, K569, D570, P571, P572, F573, I591, K593, D596, E598, A600, Q602, P603, C604</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>A: N30, T31, A32, S50, F53, H91, Y92, T94; B: Y33, R50, Y57, R59, G103, Y105</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>751.0</ContactAreaForAntigen>
                                <ContactAreaForAntibody>694.9</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

